Adverum Biotechnologies

Part of Eli Lilly and Company

CompanyUnited States

Adverum Biotechnologies develops one asset, in phase 3 (ixoberogene soroparvovec in neovascular age-related macular degeneration). Mostly gene therapy; based in the United States.

1
Asset
Furthest stage: Phase 3
Raised: $240M; 4
Trials: 0
Signals

Pipeline

1

ixoberogene soroparvovec
Delivers an aflibercept gene to retinal cells for sustained inhibition of angiogenic growth factors.
Phase 3, Gene therapy, neovascular age-related macular degeneration, wet age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

In the full profile

Trials4
Funding rounds and grants6
People13
Signals2
Similar companies6